article thumbnail

Why Proviral DNA Drug Resistance Testing is Useful in Guiding Treatment Decisions for HIV-1 Patients

XTalks

However, the variant viral genomes will still persist in the latent reservoir as provirus and can be detected with proviral DNA testing. In contrast to HIV RNA, HIV proviral DNA remains present in a patient’s cells even during virological suppression. Proviral DNA Genotyping. HIV Drug Resistance Testing.

DNA 98
article thumbnail

#news #biotech GTEx Consortium releases fresh insights into how DNA differences govern gene expression

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: GTEx Consortium releases fresh insights into how DNA differences govern gene expression.Scientists from the Genotype-Tissue Expression (GTEx) project, a National Institutes of Health-funded consortium including researchers from (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New whitepaper on trends in precision medicine: Cancer

Drug Discovery World

Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. Standard treatment for some cancers now include genotyping or molecular imaging in living patients.

article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. In the next decade, ‘recontact by genotype’ to identify people at-risk or living with genetic diseases who are eligible for a new therapy or clinical trial will be a major force shaping research and healthcare.

article thumbnail

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Delveinsight

Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment durations (usually 8–12 weeks). and GT2 and GT3 with ribavirin.

article thumbnail

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms.

Genome 119
article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

Moreover, the test will also allow clinicians to monitor the evolution of a patient’s tumor genotype during the course of therapy through serial and almost real-time assessments; this will help to better guide treatment decisions and care. In the US, Medicare covers the test.

Gene 105